Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies

To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D).

[1]  A. Salsali.  Review for "Long‐Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52‐Week Outcomes from the DEPICT‐1 and ‐2 Studies" , 2020 .

[2]  O. Tomonaga,et al.  Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial , 2019, Diabetes, obesity & metabolism.

[3]  B. Zinman,et al.  Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol , 2019, Diabetes, obesity & metabolism.

[4]  I. Dicembrini,et al.  Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials , 2019, Acta Diabetologica.

[5]  S. Edelman,et al.  Sodium‐glucose co‐transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials , 2019, Diabetes, obesity & metabolism.

[6]  T. Oron,et al.  International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors , 2019, Diabetes Care.

[7]  M. Phillip,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.

[8]  B. Zinman,et al.  Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials , 2018, Diabetes Care.

[9]  S. Garg,et al.  Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. , 2018, Diabetes technology & therapeutics.

[10]  C. Mathieu,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial , 2018, Diabetes Care.

[11]  V. Vallon,et al.  The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus , 2018, Drugs.

[12]  S. PatelNeha,et al.  Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. , 2017 .

[13]  M. Phillip,et al.  Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[14]  O. Hamdy,et al.  Weight Management in Patients with Type 1 Diabetes and Obesity , 2017, Current Diabetes Reports.

[15]  K. Brodovicz,et al.  Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review , 2017, BMJ Open.

[16]  R. Schmieder,et al.  A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation , 2017, Cardiovascular Diabetology.

[17]  W. Tamborlane,et al.  Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. , 2017, Diabetes technology & therapeutics.

[18]  M. Matsuhisa,et al.  Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus , 2017, Advances in Therapy.

[19]  S. Ito,et al.  Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study , 2016, Journal of clinical medicine research.

[20]  R. Henry,et al.  Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.

[21]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[22]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[23]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[24]  A. Rosengren,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2014, The New England journal of medicine.

[25]  B. Zinman,et al.  Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association , 2014, Diabetes Care.

[26]  D. Nathan,et al.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.

[27]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[28]  V. Woo,et al.  Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.

[29]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[30]  J. N. Fisher,et al.  Hyperglycemic Crises in Adult Patients With Diabetes , 2009, Diabetes Care.

[31]  P. Norwood,et al.  A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers , 2009, Diabetes Care.

[32]  B. Kestenbaum,et al.  Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. , 2008, Archives of internal medicine.

[33]  D. Gordin,et al.  Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes , 2007, Diabetologia.

[34]  Workgroup on Hypoglycemia.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.

[35]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.